Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$46.91B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.11 | 2.71%
Avg Daily Range (30 D):	$18.26 | 3.82%
Avg Daily Range (90 D):	$13.97 | 3.08%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	1.02M
Avg Daily Volume (90 D):	.95M

Trade Size
Avg Trade Size (Sh.):	60
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	21

Institutional Trades
Total Institutional Trades:	3,755
Avg Institutional Trade:	$17.52M
Avg Institutional Trade (30 D):	$39.67M
Avg Institutional Trade (90 D):	$32.07M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$31.35M
Avg Closing Trade (30 D):	$87.46M
Avg Closing Trade (90 D):	$67.55M
Avg Closing Volume:	90.74K

News

Jul 8, 2026 @ 8:25 AM 2 Stocks Down Over 30% to Buy Right Now and Hold f... Source: John Ballard

Jul 5, 2026 @ 7:05 AM 3 Magnificent Growth Stocks to Buy in July Source: Jennifer Saibil

Jul 2, 2026 @ 9:05 AM Will SpaceX Soar After It Joins the Nasdaq-100? Hi... Source: Adria Cimino

Jun 16, 2026 @ 4:15 PM From TASER to the Skies. Buy Axon Stock While It's... Source: Justin Pope

Jun 11, 2026 @ 5:36 PM S&P 500 Rebound Looks Fragile as Chip Strength Mas... Source: Itai Smidt

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.11	$.03	$1.6
Diluted EPS	$2.05	$.03	$1.51
Revenue	$807.35M	$796.72M	$2.78B
Gross Profit	$477.29M	$461.3M	$1.66B
Net Income / Loss	$169.31M	$2.75M	$124.66M
Operating Income / Loss	$29.24M	$-50.12M	$-62.08M
Cost of Revenue	$330.06M	$335.43M	$1.12B
Net Cash Flow	$-742.24M	$-222.75M	$746.63M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1